



REF C9300150A 1x50ml Turbidimetry

Quantitative determination of human complement C3 (C3)

Store 2 - 8°C

INTENDED USE

The C3 is a quantitative turbidimetric test for the measurement of complement C3 in human serum or plasma.

PRINCIPLE OF THE METHOD

Anti-human C3 antibodies when mixed with samples containing C3, form insoluble complexes. These complexes cause an absorbance change, dependent upon the C3 concentration of the patient sample, that can be quantified by comparison from a calibrator of know C3 concentration.

CLINICAL SIGNIFICANCE¹

C3 is the functional link between classical and alternative pathways of activation and it is the most concentrate component of the complement system in human plasma. Hepatic cells synthesize C3, although bacterial endotoxins induce synthesis by monocytes and fibroblasts

Concentration C3 increases as a consequence of an acute-phase response (trauma, surgery or inflammatory process), biliary obstruction and focal glomerulosclerosis. Decreasing C3 levels are consequence of a genetic deficiency that may increase the risk of infections particularly with encapsulated bacteria, or acquired deficiency that causes vascular disorders and severe infections.

| Diluent (R1) | Tris buffer 20 mmol/L, PEG 8000, pH 8.3. Sodium azide 0.95 g/L. |
|---------------|--|
| Antibody (R2) | Goat serum, anti-human C3, pH 7.5. Sodium azida 0.95 g/L. |

The assay is calibrated to the Reference Material CRM 470/RPPHS (Institute for Reference Materials and Measurements). It must be used the SERUM PROTEINS CALIBRATOR (Cod.:905CAL) to calibrate the reagent. The reagent (both monoreagent and bireagent) should be recalibrated every month, when the controls are out of specifications, and when changing the reagent lot or the instrument settings.

PREPARATION

Reagents: Ready to use.

Calibration Curve: Prepare the following SERUM PROTEINS CALIBRATOR dilutions in NaCl 9 g/L as diluent. Multiply the concentration of the C3 calibrator by the corresponding factor stated in table bellow to obtain the C3 concentration of each dilution.

| Calibrator dilution | 1 | 2 | 3 | 4 | 5 | 6 |
|---------------------|-----|-----|------|-----|------|-----|
| Calibrator (µL) | | 10 | 25 | 50 | 75 | 100 |
| NaCl 9 g/L (µL) | 100 | 90 | 75 | 50 | 25 | - |
| Factor | 0 | 0.1 | 0.25 | 0.5 | 0.75 | 1.0 |

STORAGE AND STABILITY

All the components of the kit are stable until the expiration date on the label when stored tightly closed at 2-8°C and contaminations are prevented during their use. Do not use reagents over the expiration date.

Reagent deterioration: The presence of particles and turbidity. Do not use

Do not freeze; frozen Antibody or Diluent could change the funcitionality of the test.

ADDITIONAL EQUIPMENT

- Thermostatic bath at 37°C
- Spectrophotometer or photometer thermostatable at 37°C with a 340 nm filter(320 - 360 nm)

SAMPLES

Fresh serum or plasma. EDTA or heparin should be used as anticoagulant. Stable 7 days at 2-8°C or 3 months at -20°C.

The samples with presence of fibrin should be centrifuged.

Do not use highly hemolized or lipemic samples

PROCEDURE

- 1. Bring the reagents and the photometer (cuvette holder) to 37°C.
- Assay conditions:

Wavelength: 340 nm Temperature: 37 °C Cuvette ligth path: 1cm

Adjust the instrument to zero with distilled water.

| Pipelle into a cuvelle. | | | | |
|-------------------------|--------|--|--|--|
| Reagent R1 | 800 μL | | | |
| Sample or Calibrator | 10 μL | | | |

5. Mix and read the absorbance (A₁) after the sample addition

Immediately, pipette into the cuvette:

Reagent R2 200 uL

7. Mix and read the absorbance (A2) of calibrators and sample exactly 5 minutes after the

Gesan has instruction sheets for several automatic analyzers. Instructions for many of them are available on request.

Calculate the absorbance difference (A2-A1) of each point of the calibration curve and plot the values obtained against the C3 concentration of each calibrator dilution. C3 concentration in the sample is calculated by interpolation of its (A_2-A_1) in the

QUALITY CONTROL

Control sera are recommended to monitor the performance of manual and automated assay procedures. Gesan SERUM PROTEINS CONTROL (Cod.:905CTL). Each laboratory should establish its own Quality Control scheme and corrective actions if controls do not meet the acceptable tolerances.

REFERENCE VALUES⁵

Neonates: Between 70 - 196 mg/dL. Adults: Between 90 – 180 mg/dL.

Each laboratory should establish its own reference range.

PERFORMANCE CHARACTERISTICS

- Measurement range: Up to 400 mg/dL, under the described assay conditions. Samples with higher concentrations, should be diluted 1/5 in NaCl 9 g/L and retested again. The linearity limit and measurement range depends on the sample to reagent / ratio. It will be higher by decreasing the sample volume, although the sensitivity of the test will be proportionally decreased.

 2. **Detection Limit**: Values less than 1 mg/dL give non-reproducible results.

 3. **Prozone effect**: No prozone effect was detected upon 1500 mg/dL.

 4. **Sensitivity**: \triangle 8.86 mA. mg/dL (23.8 mg/dL), \triangle 84.3 mA. mg/dL (190 mg/dL).

- 5. Precision: The reagent has been tested for 20 days, using three levels of serum in a EP5-based study.

| EP5 | CV (%) | | | | | |
|-------------|-------------|--------------|-------------|--|--|--|
| | 42.98 mg/dl | 118.96 mg/dl | 229.5 mg/dl | | | |
| Total | 6.6% | 2.3% | 3.1% | | | |
| Within Run | 0.9% | 0.8% | 0.8% | | | |
| Between Run | 3.7% | 2.2% | 1.8% | | | |
| Between Day | 5.4% | 0% | 2.4% | | | |

6. Accuracy: Results obtained using this reagent (y) were compared to those obtained using an immunoturbidimetric method from Bayer. 48 samples ranging from 50 to 200 mg/dL of C3 were assayed. The correlation coefficient (r) was 0.96 and the regression equation y = 1.1x - 0.6.

The results of the performance characteristics depend on the used analyzer.

INTERFERENCES

Hemoglobin (19 g/L), bilirrubin (40 mg/dL) and rheumatoid factors (600 IU/mL), do not interfere. Lipemia (10 g/L), interferes. Other substances may interfere.

NOTES

Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

BIBLIOGRAPHY

- . Clinical Guide to Laboratory Tests, Edited by NW Tietz W B Saunders Co., Phipladelphia, 483, 1983. 2. Carrol MC. Annual Review of Immunology 1998; 16: 545-568.
- 3. Lambris JD. Cruse JM Lewis RE Jr (eds): Complement Today. Complement Profiles. Basel, Karger, 1993; Vol1: 16-45.
- 4. Pesce AJ and Kaplan, LA. Methods in Clinical Chemistry. The CV Mosby Company, St. Louis MO, 1987.
- 5. Dati F et al. Eur J Clin Chem Clin Biochem 1966; 14: 401-406
- 6. Young DS. Effects of disease on clinical laboratory tests, 3th ed. AACC Pres, 1997
- 7. Friedman and Young. Effects of disease on clinical laboratory tests, 3tn ed. AACC Pres, 1997.

PACKAGING

Ref.: C9300150/C9300150A 1 x 40 mL R1. Diluent 1 x 10 mL R2. Antibody

Simbols

CE Mark (requirement of 98/79 (€ regulation) IVD in vitro medical device LOT **Batch Code** Use by Storage temperature limits

Ti Read instruction for use

Gesan Production srl